| KRYSTAL BIOTECH DL-,00001 |
| USA |
| Gesundheit |
| US5011471027 / A2JH2F |
| 4KB (Frankfurt) / KRYS (NASDAQ) |
| FRA:4KB, ETR:4KB, 4KB:GR, NASDAQ:KRYS |
| - |
| https://www.krystalbio.co.. |
|
Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for serious and rare diseases. Its lead product, VYJUVEK, is a redosable gene therapy approved ..
>Volltext.. |
| 9294.52 Mio. EUR |
| 8561.5 Mio. EUR |
| 380.17 Mio. EUR |
| 176.42 Mio. EUR |
| 208.4 Mio. EUR |
| 7.14 EUR |
| 7.64 Mio. EUR |
| 369.17 Mio. EUR |
| 235.04 Mio. EUR |
| 6.64 |
| 26.49% |
| 69.75% |
| - |
| - |
| - |
| 3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 22.554.027 Euro. |
| KRYSTAL BIOTECH |
| 05.09.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|